Beyond Air Inc (XAIR): יחס שווי פעילות לרווח לפני ריבית, מסים ופחת

Beyond Air, Inc. (XAIR) is implementing AI modules for device management and automating patient tracking. The company is expanding its presence in US clinics by promoting the LungFit system for therapeutic gas generation. This EV/EBITDA chart, with a value of 0.00, complements the business analysis. The brand's ecosystem replaces bulky cylinders with autonomous devices, creating a safe environment for the therapy of severe lung infections.

This ratio compares the total enterprise value, including net debt, to operating profit before taxes and amortization, allowing for an assessment of the real value of assets relative to their yield. For Beyond Air, Inc. (XAIR), which is developing innovative nitric oxide therapy, the EV/EBITDA multiple reflects the balance between capital expenditures for expansion and the efficiency of its medical solutions, signaling the company's degree of leverage to the investor.